Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
1.78B | 1.48B | 872.00M | 526.92M | 271.88M | 148.76M | Gross Profit |
1.37B | 1.17B | 714.95M | 408.72M | 204.49M | 109.45M | EBIT |
109.90M | 61.90M | -29.45M | -68.70M | -115.04M | -15.14M | EBITDA |
132.26M | 78.99M | -19.94M | -61.22M | -110.97M | -14.09M | Net Income Common Stockholders |
164.40M | 126.04M | -23.55M | -65.68M | -107.66M | -18.11M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
203.59M | 300.25M | 220.98M | 179.63M | 247.27M | 100.21M | Total Assets |
448.11M | 707.54M | 441.19M | 366.34M | 420.58M | 118.70M | Total Debt |
11.82M | 11.35M | 9.95M | 5.31M | 5.48M | 0.00 | Net Debt |
-93.41M | -209.24M | -86.72M | -41.47M | -66.30M | -27.34M | Total Liabilities |
103.62M | 230.82M | 97.16M | 54.60M | 85.97M | 265.57M | Stockholders Equity |
344.48M | 476.72M | 344.03M | 311.74M | 334.62M | -146.87M |
Cash Flow | Free Cash Flow | ||||
240.22M | 209.43M | 46.99M | -33.78M | -39.42M | -6.71M | Operating Cash Flow |
334.34M | 251.08M | 73.48M | -26.53M | -34.41M | -2.48M | Investing Cash Flow |
-64.89M | -19.05M | -12.11M | 34.70M | -156.27M | -39.70M | Financing Cash Flow |
-100.56M | -107.84M | -11.47M | -33.13M | 235.04M | 47.74M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
80 Outperform | $4.39B | 26.58 | 22.16% | 2.22% | 10.32% | 18.55% | |
77 Outperform | $12.25B | 78.03 | 36.79% | ― | 85.99% | ― | |
69 Neutral | $1.25B | 15.48 | 5.53% | 2.26% | -2.11% | -28.79% | |
67 Neutral | $6.47B | 61.05 | 15.97% | ― | 46.27% | -26.45% | |
60 Neutral | $4.34B | 40.12 | -10.58% | ― | -1.68% | -302.11% | |
54 Neutral | $389.37M | ― | -4.93% | 3.04% | -11.85% | -1080.00% | |
53 Neutral | $5.25B | 3.24 | -45.38% | 2.81% | 16.79% | -0.06% |
On May 13, 2025, Hims & Hers Health issued $1 billion in senior unsecured notes, which are equal in payment rights to the company’s existing and future senior unsecured debts but are subordinate to secured debts. These notes, maturing on May 15, 2030, offer conversion options into Class A common stock under specific conditions and include provisions for redemption and repurchase under certain corporate events. Additionally, the company engaged in capped call transactions to mitigate potential stock dilution from note conversions, with a cap price set at $89.95 per share, representing a 75% premium over the stock’s last reported sale price on May 8, 2025.
The most recent analyst rating on (HIMS) stock is a Hold with a $40.00 price target. To see the full list of analyst forecasts on Hims & Hers Health stock, see the HIMS Stock Forecast page.
On May 8, 2025, Hims & Hers Health, Inc. announced a proposed private offering of $450 million in Convertible Senior Notes due 2030, aimed at qualified institutional buyers. The proceeds from this offering are intended to support the company’s global expansion and investment in AI and personalized healthcare solutions, reflecting Hims & Hers’ strategic focus on scaling access to high-quality, personalized care. The offering is expected to enhance the company’s market positioning by funding organic growth and potential acquisitions, although no definitive acquisition agreements are in place at this time.
On April 21, 2025, Melissa Baird, the Chief Operating Officer of Hims & Hers Health, announced her plan to transition into an advisory role with the company. Her departure date is yet to be determined, but she will remain until a successor is found to ensure a smooth transition, and a long-term agreement will be established to retain her expertise.